Maze Therapeutics (MAZE) Earnings Date & Reports

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

MAZE is expected to report earnings to rise 26.67% to -56 cents per share on August 18

Maze Therapeutics MAZE Stock Earnings Reports

Q2'26

Est.

$-0.57

Q1'26

Beat

by $0.13

Q4'25

Missed

by $0.02

Q3'25

Missed

by $0.04

Q2'25

Missed

by $0.15

The last earnings report on May 12 showed earnings per share of -44 cents, beating the estimate of -57 cents. With 85.03K shares outstanding, the current market capitalization sits at 1.53B.

View a ticker or compare two or three

MAZE

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days